Recursion Pharmaceuticals Inc. (Nasdaq: RXRX) and Exscientia plc (Nasdaq: EXAI) have announced a landmark merger, combining their strengths to form a formidable entity in drug discovery and development. This strategic union is set to enhance their technological capabilities and expand their clinical pipeline, paving the way for more effective and affordable medicines. Key Details of […]
Pennsylvania-based Alliqua BioMedical has announced a significant merger with San Francisco’s Adynxx, aiming to establish a clinical-stage pharmaceutical entity dedicated to non-opioid pain management therapies. This strategic move promises to revolutionize pain treatment by developing disease-modifying solutions. Under the terms of the merger, Adynxx stockholders will emerge as the primary owners of Alliqua’s outstanding common […]
Takeda Pharmaceutical, a major Japanese pharmaceutical company, has made a $62 billion offer to acquire Shire, an Ireland-based leader in rare disease treatments. This proposal, Takeda’s fourth attempt to purchase Shire, comes after Shire had previously rejected three offers, citing undervaluation of its business and future growth prospects. Escalation in Acquisition Offers The latest bid […]